FDA Accepts Anaphylm NDA Resubmission, Sets March 2027 PDUFA Date, Delaying Launch by Over a Year

What happened

Aquestive Therapeutics announced that the FDA has accepted its resubmitted New Drug Application for Anaphylm and set a PDUFA goal date of March 16, 2027. This resubmission follows an earlier regulatory setback, as the original PDUFA date was January 31, 2026, meaning the approval and commercial launch are now delayed by over a year. The FDA classified the resubmission as a Class 2 response, which typically indicates a review period of six months from submission, but the new goal date suggests the agency needed additional time. Management frames the news positively, highlighting the potential for Anaphylm to be the first oral rescue medication for anaphylaxis, but this glosses over the fact that the product remains unapproved and faces intense competition from neffy and generic auto-injectors. The delay increases the company's cash burn and balance sheet strain, as Aquestive must continue funding operations without Anaphylm revenue, and the extended timeline raises the likelihood of further dilutive financing.

Implication

Investors should lower their near-term expectations and reassess the risk-reward, as the original investment thesis assumed approval by early 2026 and a commercial launch in 2026, which is now impossible. The extended timeline means Anaphylm revenue, if approved, will not materialize until late 2027 at the earliest, pushing out the company's path to profitability and increasing cumulative cash burn. Aquestive's balance sheet is already strained with negative equity, high-coupon debt, and layered royalties, and the delay heightens the risk of dilutive equity raises or distressed refinancing. Meanwhile, competitors like neffy are gaining market share and payer relationships, making it harder for Anaphylm to achieve the pricing and uptake assumed in bullish scenarios. Given the increased uncertainty, we maintain our POTENTIAL SELL rating and would trim positions above $8.50, and only consider a speculative entry near $4.50 or lower after further evidence of regulatory progress or a significant de-risking event.

Thesis delta

The thesis shifts from a near-term binary catalyst to a longer, higher-risk regulatory and commercial path. The delay reduces the probability of the bull case and increases the probability of the bear case, as the company must survive without Anaphylm revenue for an additional year. The original POTENTIAL SELL rating is reinforced, with an even lower attractive entry point justified by the extended uncertainty.